Chinese Journal of New Drugs 2011 Issue 17 Progress in imatinib adjuvant therapy of gastrointestinal stromal tumor

Progress in imatinib adjuvant therapy of gastrointestinal stromal tumor
JIANG Wei-zhong

..............page:1657-1660

A perspective,open-label,and multi-center phase Ⅱ study of FOLFOX 4 regimen as systemic therapy for patients with unresectable hepatocellular carcinoma
GONG Xin-lei1;QIN Shu-kui1;WANG Ya-jie2;XING Bao-cai3;WU Qing4;CAO Meng-ran1;HUA Hai-qing1;LIU Xiu-feng1

..............page:1673-1677

Interpretation of drugs for advanced non-small cell lung cancer in 2011
XING Pu-yuan;SHI Yuan-kai

..............page:1643-1646,1666

Progress in the study of T cell-dependent antibody response
HUO Yan;AI Wen-chao;Miao Yu-fa;Shen Lian-zhong;LI Bo

..............page:1620-1623,1672

Mechanism underlying the anti-angiogenetic effect of the novel tubulin inhibitor C9
REN Xuan;LIN Li-ping;DING Jian

..............page:1703-1710

di er jie zhong guo yi yuan yao xue lun tan long zhong zhao kai , shou ci da jian lin chuang yi shi he yao shi de jiao liu gou tong ping tai , quan guo ren da chang wei hui fu wei yuan chang sang guo wei zuo zhu ti bao gao

..............page:1581

Influence of new neoadjuvant chemotherapy on the prognosis and the protein expression of CD44v6 and p27 in patients with colorectal cancinoma
SUN Xiu-mei1;GAO Feng2;LI Gui-xin1;LIU Kang1

..............page:1695-1698

Efficacy of compound radix sophorae flavescentis injection in the prevention of radiation stomatitis
HAO Jian-qing

..............page:1699-1700

Consideration of exposure-response relationships during clinical trials of new drugs
WEI Min-ji1;ZHAO Ming2;SHAN Ai-lian1

..............page:1608-1611

Comparison of Chinese clinical trial regulation system with relevant international law
YAN Yong-bo1;2;LI Ye1

..............page:1612-1614,1619

Application status of small molecule targeted anti-cancer drugs in China
CHEN Xiao-yuan;ZHANG Hong;GAO Chen-yan;YANG Zhi-min

..............page:1615-1619

Current status of research and development of new tyrosine kinase inhibitors
ZHOU Bing-ying1;2;AN Chun-na1;2;PU Xiao-ping1;2

..............page:1661-1666

Phase I clinical trial of lyophilized recombinant human luteinizing hormone releasing hormone-exotoxin of pseudomonas aeruginosa fusion protein
ZHOU Ai-ping1;DU Chun-xia1;LIU Peng1;SUN Yong-kun1;WU Guang-mou2;ZHU Ping2;WANG Jin-wan1

..............page:1683-1687

Synthesis and anti-tumor effect of(5-fluorouracil-1-acetic acid)-4′-curcuminate
WU Min1;LIU Yang1;2;WEI Xiao-xia1;GUO Xiao-dan1;HUANG Xiu-wang1;2;DENG Yan-ping1;2;XU Jian-hua1;2

..............page:1711-1714,1677

Pharmacological effects and clinical research of the new drug crizotinib for treating lung cancer
WANG Yan;YU Shu-fei

..............page:1602-1607

Targeted therapy for non-small-cell lung cancer using EGFR-TKIs
TAN Fen-lai1;WANG Yin-xiang1;YUAN Xiao-fen1;DING Lie-ming1;HU Bei2;ZHANG Li2;ZHOU Jian-ying3;SHENG-TU Jian-zhong3;SUN Yan4

..............page:1594-1601

juan shou yu
sun yan

..............page:1587

Efficacy of composite matrine injection combined with chemotherapy in the treatment of advanced cancer
WEI Ai-fang;ZHANG Fa-en;LAN Chuan;WEI Song;WEI Jin-hua

..............page:1688-1690

Tolerability of famitinib malate:the preliminary results from phase I clinical trial
ZHOU Ai-ping;ZHANG Wen;CHANG Chun-xiao;CHI Yi-he-ba-li;WANG Jin-wan

..............page:1678-1682,1690

Interpretation of the principles of pharmacotherapy in Chinese Guideline for Renal Cell Carcinoma 2011
SHOU Jian-zhong;MA Jian-hui

..............page:1647-1651

di si jie bian wei hui di san ci hui yi zhao kai

..............page:1582

shi jie xin yao zhi chuang

..............page:1592-1593

Synthesis and structural characterization of miriplatin,a platinum-based anti-tumor drug
WANG Qing-kun1;2;PU Shao-ping1;2;3;LUAN Chun-fang1;2; CONG Yan-wei1;2;ZHANG Qi1;2;BEI Yu-xiang1;2

..............page:1715-1717

Central composite design optimizes preparation of norcantharidin-loaded chitosan-fibroin microspheres for embolization
ZHANG Guang-yu;CHI Mei-yu;NI Jing;CHEN Yuan-lan; SONG Yu-ling;WANG Xiao-qing;ZHANG Xue-nong

..............page:1624-1630

Traditional Chinese medicine and cancer:historic deposits and 50-years innovation and development
LIN Hong-sheng;ZHANG Ying

..............page:1639-1642

Further improving research quality in cancer management by integration of traditional Chinese medicine and modern medicine
SUN Yan

..............page:1588-1591,1611

Advance in research of cyclin-dependent kinase 2 inhibitors based on the structures of target proteins
BAI Xiao-guang1;XU Le-xing1;LI Yi-liang2;WANG Yu-cheng1;WANG Ju-xian1

..............page:1667-1672

Impact of early intervention on chronic CML patients with imatinib failure and the selection of second-generation TKIs
ZHOU Li

..............page:1652-1656

Effect of composite matrine injection on cyclinB2 in blood of patients with advanced nasopharyngeal squamous cell carcinoma
WANG Jian-gong1;WANG Xiao-hong2;HU Wan-ning1;LIU Wei-dong2;YANG Jun-quan2

..............page:1691-1694

Safety considerations in children:L-asparaginase-induced adverse drug reactions
HUANG Lin;LIU Yi;REN Xiao-lei;LI Yu-zhen

..............page:1723-1726

Preparation of lactosyl-norcantharitin phospholipid complex and its pH-sensitive liposomes
ZHOU Yi;XU Jing-yu;GUAN Min;ZAHNG Xue-nong

..............page:1631-1638

Antitumor effect and mechanism of the cyclophosphamide derivative SLXM-2 on B₂₂ brain tumor in mice
ZHONG Guo1;XU Bo1;GUO Wei1;GE Ze-mei2;LI Run-tao2;CUI Jing-rong1

..............page:1718-1722,1726

Effect of matrine injection in 58 gastrointestinal cancer patients with postoperative chemotherapy
LIN Heng-jun;FU Bao-juan;LOU Li-xin

..............page:1701-1702,1710